These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27131465)

  • 1. Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.
    Ory J; Flannigan R; Lundeen C; Huang JG; Pommerville P; Goldenberg SL
    J Urol; 2016 Oct; 196(4):1082-9. PubMed ID: 27131465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
    Pastuszak AW; Khanna A; Badhiwala N; Morgentaler A; Hult M; Conners WP; Sarosdy MF; Yang C; Carrion R; Lipshultz LI; Khera M
    J Urol; 2015 Nov; 194(5):1271-6. PubMed ID: 26025500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
    Yassin A; Salman M; Talib RA; Yassin DJ
    Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
    Shoskes DA; Barazani Y; Fareed K; Sabanegh E
    Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
    Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy.
    Ahlering TE; My Huynh L; Towe M; See K; Tran J; Osann K; El Khatib FM; Yafi FA
    BJU Int; 2020 Jul; 126(1):91-96. PubMed ID: 32124531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone therapy in men with untreated prostate cancer.
    Morgentaler A; Lipshultz LI; Bennett R; Sweeney M; Avila D; Khera M
    J Urol; 2011 Apr; 185(4):1256-60. PubMed ID: 21334649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy.
    Shahine H; Zanaty M; Zakaria AS; Nguyen DD; Couture F; Sadri I; Schwartz R; Arezki A; Elterman D; El-Hakim A; Zorn KC
    World J Urol; 2021 Sep; 39(9):3223-3229. PubMed ID: 33034733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
    J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.
    Sarkar RR; Patel SH; Parsons JK; Deka R; Kumar A; Einck JP; Mundt AJ; Kader AK; Kane CJ; Riviere P; McKay R; Murphy JD; Rose BS
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):689-695. PubMed ID: 32513967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
    Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
    J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
    Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
    Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.